Futura Medical (FUM) Stock Overview
Research, develops, and commercializes pharmaceutical and healthcare products for sexual health. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
FUM Community Fair Values
Create NarrativeSee what 16 others think this stock is worth. Follow their fair value or set your own to get alerts.
Futura Medical plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.012 |
| 52 Week High | UK£0.34 |
| 52 Week Low | UK£0.0099 |
| Beta | 0.48 |
| 1 Month Change | -47.76% |
| 3 Month Change | -87.55% |
| 1 Year Change | -96.57% |
| 3 Year Change | -97.57% |
| 5 Year Change | -93.34% |
| Change since IPO | -98.37% |
Recent News & Updates
Futura Medical plc's (LON:FUM) 57% Dip In Price Shows Sentiment Is Matching Revenues
Dec 06
Investors Don't See Light At End Of Futura Medical plc's (LON:FUM) Tunnel And Push Stock Down 75%
Oct 18Recent updates
Futura Medical plc's (LON:FUM) 57% Dip In Price Shows Sentiment Is Matching Revenues
Dec 06Investors Don't See Light At End Of Futura Medical plc's (LON:FUM) Tunnel And Push Stock Down 75%
Oct 18Benign Growth For Futura Medical plc (LON:FUM) Underpins Stock's 33% Plummet
Aug 28Futura Medical plc (LON:FUM) Shares Slammed 48% But Getting In Cheap Might Be Difficult Regardless
Jan 31Need To Know: Analysts Are Much More Bullish On Futura Medical plc (LON:FUM)
Sep 13We Think Futura Medical (LON:FUM) Can Easily Afford To Drive Business Growth
Apr 17Here's Why We're Not At All Concerned With Futura Medical's (LON:FUM) Cash Burn Situation
Jan 05Is Futura Medical (LON:FUM) In A Good Position To Invest In Growth?
Jul 28We Think Futura Medical (LON:FUM) Needs To Drive Business Growth Carefully
Mar 18We're Keeping An Eye On Futura Medical's (LON:FUM) Cash Burn Rate
Sep 25Here's Why We're Not Too Worried About Futura Medical's (LON:FUM) Cash Burn Situation
May 10We're Interested To See How Futura Medical (LON:FUM) Uses Its Cash Hoard To Grow
Jan 10What We Learned About Futura Medical's (LON:FUM) CEO Compensation
Dec 21
Shareholder Returns
| FUM | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 5.9% | -1.5% | -0.2% |
| 1Y | -96.6% | 22.6% | 14.9% |
Return vs Industry: FUM underperformed the UK Pharmaceuticals industry which returned 22.6% over the past year.
Return vs Market: FUM underperformed the UK Market which returned 14.9% over the past year.
Price Volatility
| FUM volatility | |
|---|---|
| FUM Average Weekly Movement | 22.8% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 10.8% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: FUM's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: FUM's weekly volatility has increased from 17% to 23% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 14 | n/a | www.futuramedical.com |
Futura Medical plc research, develops, and commercializes pharmaceutical and healthcare products for sexual health. The company’s lead product includes Eroxon, a topical gel for the treatment of erectile dysfunction. It also develops WSD4000 for the treatment of sexual dysfunction in women.
Futura Medical plc Fundamentals Summary
| FUM fundamental statistics | |
|---|---|
| Market cap | UK£3.57m |
| Earnings (TTM) | -UK£6.29m |
| Revenue (TTM) | UK£7.93m |
Is FUM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FUM income statement (TTM) | |
|---|---|
| Revenue | UK£7.93m |
| Cost of Revenue | UK£2.81m |
| Gross Profit | UK£5.11m |
| Other Expenses | UK£11.41m |
| Earnings | -UK£6.29m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.021 |
| Gross Margin | 64.49% |
| Net Profit Margin | -79.41% |
| Debt/Equity Ratio | 0% |
How did FUM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/08 22:56 |
| End of Day Share Price | 2025/12/08 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Futura Medical plc is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Francesco Gregori | Edison Investment Research |
| Sebastien Jantet | Panmure Liberum |
| Brian White | Shore Capital Group Ltd |